Large Volume Wearable Injectors: from Conception to Reality

The focus of the latest edition is to provide a comprehensive analysis of the current state of the market, including detailed sales forecasts of these devices over the next ten years.

Chandigarh, India, June 26, 2015 --( Roots Analysis has announced the addition of “Large Volume Wearable Injectors, 2014-2025” report to its portfolio. The report is the second edition of the original publication titled “Bolus Injectors, 2014-2024” released in 2013. The focus of the latest edition is to provide a comprehensive analysis of the current state of the market, including detailed sales forecasts of these devices over the next ten years. Also known as bolus injectors and non-insulin patch pumps; these injectors not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry.

The absence of devices which can safely allow patients to self-administer large volume / highly viscous drugs is currently a big unmet need in the market. Despite the uncertainties related to the device development and approval, many established firms such as Becton Dickinson, West Pharmaceuticals and emerging players such as Unilife, SteadyMed Therapeutics, Ratio Drug Delivery, Sensile Medical, Enable Injections and scPharmaceuticals are heavily investing their time, money and resources to develop novel devices.

Rupali Verma, the principal analyst, said, “Our latest research has allowed us to further distil the list of over 250 drug-disease combinations that we had in the last year’s edition. You may remember that the starting point for us was over 900 biologics, most of which are currently in the pipeline. In the revised edition, we have lowered the ~250 drug-disease combinations to ~180. These 180 drug-disease combinations have been further categorized based upon their likely potential for delivery via bolus injectors in the future.”

Amongst other things, the report also includes detailed case studies on specific drugs such as Herceptin, AMG-145, Furosemide, Cephalosporin and ND0612L currently being targeted for delivery via large volume wearable injectors. The report extensively examines the insights gathered from interviews of important stakeholders such as West Pharmaceutical Services, Ratio Drug Delivery, Enable Injections and scPharmaceuticals.

Verma further stated, “One of the primary objectives of this report was to estimate size of the future promise offered by these injectors, which are currently available only for investigational use. By 2025, we expect more than 300 million units to be sold annually.”

In addition to the market forecasts over the next ten years (both in terms of volume and value), the report clearly identifies the various challenges and opportunities in the short and long term.

Who should buy this report?
This research is targeted towards big / small pharma companies which are working in the field of drug delivery and development. As biologics continue to grab an increasing share of the drugs market, their ease of administration is likely to play a prominent role. In particular, you could benefit from this report if you are looking to

-Develop a comprehensive knowledge of the various bolus injector devices (usage mechanism, advantages, status of development)
-Understand the competition and opportunities shaping this industry
-Identify various drug-disease combinations that are likely to be a target for delivery via bolus injectors
-Ascertain the likely volume of these devices and corresponding market size over the next ten years
-Establish the right partnerships to either grow or enter this sector

About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Roots Analysis
Ashish Ganguli